Product Description: WYE-354 is an ATP-competitive mTOR inhibitor with an IC50 of 5 nM. WYE-354 also inhibits PI3Kα and PI3Kγ with IC50s of 1.89 μM and 7.37 μM, respectively. WYE-354 inhibits both mTORC1 and mTORC2. WYE-354 induces autophagy activation in vitro[3].
Applications: Cancer-Kinase/protease
Formula: C24H29N7O5
References: [1]Yu K et al. Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin. Cancer Res. 2009 Aug 1;69(15):6232-40./[2]Weber H, et al. Rapamycin and WYE-354 suppress human gallbladder cancer xenografts in mice. Oncotarget. 2015 Oct 13;6(31):31877-88./[3]Lijun Wang, et al. Autophagy inhibition sensitizes WYE-354-induced anti-colon cancer activity in vitro and in vivo. Tumour Biol. 2016 Sep;37(9):11743-11752.
CAS Number: 1062169-56-5
Molecular Weight: 495.53
Compound Purity: 98.04
Research Area: Cancer
Solubility: DMSO : 6.67 mg/mL (ultrasonic)
Target: Apoptosis;Autophagy;mTOR
Deutsch
English
